ClinicoEconomics and Outcomes Research最新文献

{"title":"Evaluating the Fiscal Burden of Essential Thrombocythemia in Sweden Through Application of a Government Perspective.","authors":"Cillian Copeland, Mark P Connolly, Vivek Khurana, Sara Ottosson, Inkyu Kim, Stina Salomonsson","doi":"10.2147/CEOR.S626997","DOIUrl":"https://doi.org/10.2147/CEOR.S626997","url":null,"abstract":"<p><strong>Introduction: </strong>Essential thrombocythemia (ET) is a myeloproliferative neoplasm (MPN) with an annual incidence of 1.6 per 100,000 people in Sweden. ET causes a range of symptoms and increased risk of hemorrhagic and thrombotic events, which contribute to a significant clinical burden. ET can also impair daily functioning and work ability, leading to reduced labor force participation and indicating that its burden extends beyond the healthcare system. While the clinical aspects of ET are well described, evidence on its broader fiscal impact remains limited. This study explores the fiscal impact of ET in Sweden using a government perspective analytic framework.</p><p><strong>Methodology: </strong>A cohort-based fiscal model was developed that tracked the fiscal transactions of a cohort of individuals with ET compared to an age-matched cohort in the general population. Swedish data on economic activity, employment, productivity losses, disability, and retirement were incorporated, and the impact of ET on these outcomes was sourced from a targeted literature search. The incremental effect of ET on government tax revenue and spending on social support programs was combined with excess ET-attributable healthcare costs to generate the combined fiscal burden.</p><p><strong>Results: </strong>For a cohort of individuals with ET with a mean age of 65, the per-person fiscal loss of ET was calculated as SEK 1,721,734. This comprises tax revenue loss of SEK 766,665 from lower employment participation, income, and productivity losses (absenteeism and presenteeism), increased spending of SEK 64,771 on social support programs and healthcare costs of SEK 890,298.</p><p><strong>Conclusion: </strong>This study demonstrates that the burden of ET impacts wider government accounts by reducing productivity and economic activity and increasing rates of unemployment, long-term disability, and retirement. This fiscal burden is highest among younger individuals due to a greater number of remaining working years, while healthcare costs are the main driver among older individuals.</p>","PeriodicalId":47313,"journal":{"name":"ClinicoEconomics and Outcomes Research","volume":"18 ","pages":"626997"},"PeriodicalIF":2.6,"publicationDate":"2026-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13695362/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149275313","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Economic Value and Caregiver Burden of Continuous Fascia iliaca Compartment Block in Elderly Patients with Intertrochanteric or Subtrochanteric Fracture: A Cost-Consequence Analysis Based on a Propensity Score-Matched Cohort.","authors":"Zijian Wang, Hua Gao, Guoqiang Xu, Ji Ma, Rubing Zhou","doi":"10.2147/CEOR.S632315","DOIUrl":"https://doi.org/10.2147/CEOR.S632315","url":null,"abstract":"<p><strong>Background: </strong>Hip fracture imposes substantial clinical and economic burden on older adults in China. Continuous fascia iliaca compartment block (CFICB) may improve perioperative recovery in elderly patients with intertrochanteric or subtrochanteric fracture, but its economic consequences remain uncertain. We compared direct medical costs, caregiver-related indirect costs, and clinical outcomes of CFICB with routine systemic analgesia (RA; a non-block regimen, distinct from regional anaesthesia, of which CFICB is itself a technique).</p><p><strong>Methods: </strong>We performed a cost-consequence analysis alongside a propensity score-matched retrospective cohort study at Beijing Friendship Hospital. Patients aged ≥65 years treated January 2020-December 2023 were included after 1:1 matching (CFICB n = 40; RA n = 40). Healthcare-system and societal perspectives were adopted over a pre-specified one-month postoperative horizon. Direct costs came from itemised billing; caregiver time costs were valued by the replacement-cost approach and productivity losses by the human capital approach. Mean cost differences and 95% CIs used bias-corrected and accelerated bootstrap resampling.</p><p><strong>Results: </strong>Total hospitalisation costs did not differ significantly between groups (CFICB ¥51,346 ± 10,924 vs RA ¥52,481 ± 12,267; difference -¥1,135; 95% CI -¥6,287 to +¥4,017; P = 0.523). CFICB was associated with lower scheduled-analgesic (-¥177), opioid-rescue (-¥142), cognitive-change-management (-¥2,473), rehabilitation (-¥631), and ward-overhead costs from a 2.4-day shorter stay (-¥1,440; 12.3 vs 14.7 days; P = 0.001). Informal caregiver time costs (-¥3,249) and productivity losses (-¥2,536) were lower with CFICB, yielding caregiver-related indirect savings of ¥5,785 per patient; this reflects caregiverborne costs only, not total societal cost.</p><p><strong>Conclusion: </strong>In this single-centre matched cohort, total hospitalisation cost did not differ significantly between groups (difference -¥1,135; P = 0.523), while pre-specified downstream and caregiver-related costs were lower with CFICB. Given the small, single-centre, retrospective design, these hypothesisgenerating findings warrant cautious interpretation and support prospective, multicentre evaluation of CFICB in elderly proximal femoral fracture patients.</p>","PeriodicalId":47313,"journal":{"name":"ClinicoEconomics and Outcomes Research","volume":"18 ","pages":"632315"},"PeriodicalIF":2.6,"publicationDate":"2026-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13685685/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149246833","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cost Utility Analysis of Corneal Neurotization and Recombinant Nerve Growth Factor for Neurotrophic Keratopathy.","authors":"George A Villatoro, Arman T Yazdian, Aashka R Damani, Richard Ditto, Michael T Yen","doi":"10.2147/CEOR.S638922","DOIUrl":"https://doi.org/10.2147/CEOR.S638922","url":null,"abstract":"<p><strong>Purpose: </strong>To evaluate the cost-utility of surgical corneal neurotization (CN) versus topical recombinant nerve growth factor (cenegermin), using a Markov model from a health care system perspective, in the management of neurotrophic keratopathy (NK).</p><p><strong>Methods: </strong>Three Markov models were utilized: treatment with cenegermin, treatment with CN, and combined treatment with cenegermin and CN.</p><p><strong>Results: </strong>At the per-patient level, CN resulted in total costs of $36,866 and generated 3.66 Quality of Life Years (QALYs), whereas cenegermin resulted in costs of $161,926 and 3.32 QALYs, respectively. The combined strategy of cenegermin followed by CN resulted in costs of $137,048 and 3.82 QALYs. Probability sensitivity analysis using 1000 Monte Carlo simulations suggested that CN was associated with lower mean total costs ($15,808 vs $161,352) and higher mean QALYs (3.89 vs 3.71) when compared with cenegermin. In the comparison between CN and the combined strategy, CN remained less costly ($15,808 vs $124,962) with nearly equivalent effectiveness (3.895 vs 3.905 QALYs). At a willingness to pay (WTP) threshold of $100,000 per QALY, CN was cost-effective in 100% of simulations against cenegermin or combined CN/cenegermin strategies. By deterministic sensitivity analysis (DSA) between cenegermin and CN, CN revealed a positive net monetary benefit (NMB) across all parameter variations, most influenced by the probability of healing following cenegermin treatment, utility associated with a healed cornea and the cost of cenegermin. Incremental cost analysis suggested that CN remained the preferred strategy across the modeled parameter ranges.</p><p><strong>Conclusion: </strong>Within this five-year cost-utility model, corneal neurotization provided greater economic value and quality-of-life outcomes than cenegermin. These findings suggest that corneal neurotization may offer meaningful long-term economic and patient benefits for moderate-to-severe neurotrophic keratopathy, although results remain dependent on the clinical and economic assumptions incorporated into the model.</p>","PeriodicalId":47313,"journal":{"name":"ClinicoEconomics and Outcomes Research","volume":"18 ","pages":"638922"},"PeriodicalIF":2.6,"publicationDate":"2026-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13682333/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149239898","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cost Burden and Cost-Effectiveness of Rhegmatogenous Retinal Detachment Repair: A Systematic Review of Economic Evaluations.","authors":"Aswen Sriranganathan, Jobanpreet Dhillon, Efrem Mandelcorn, Tina Felfeli","doi":"10.2147/CEOR.S559354","DOIUrl":"https://doi.org/10.2147/CEOR.S559354","url":null,"abstract":"<p><strong>Purpose: </strong>To review the economic burden and cost-effectiveness analyses of interventions and management of rhegmatogenous retinal detachment (RRD).</p><p><strong>Patients and methods: </strong>A comprehensive literature search was conducted on Ovid Medline, Embase and Scopus from inception to March 2025 for articles reporting economic burden, cost analyses, cost-effectiveness, or cost-utility outcomes related to RRD repair. Primary outcomes were the cost of RRD adverse events and repair. Secondary outcomes were the incremental cost-effectiveness ratios (ICER) of RRD repair procedures. Risk of bias was assessed using the Joanna Briggs Institute Critical Appraisal Checklist for Economic Evaluations. The review protocol was registered in PROSPERO (CRD42023446301).</p><p><strong>Results: </strong>A total of 46 publications met the inclusion criteria and were included in the study. Most studies were conducted in the United States (48%) and adopted payer or provider analytic perspectives. In 23 studies reporting RRD as an adverse event of another condition or intervention, the mean cost of repair was $3,648±2,986, inflated to 2024 US dollars (USD). Across 22 studies assessing cost comparisons of RRD interventions, the cost of the pneumatic retinopexy (PR), pars plana vitrectomy (PPV) and scleral buckle (SB) surgery ranged from $1,093-$4,761, $5,443-$9,903, and $4,411-$8,131, respectively. Considerable heterogeneity existed across economic models, analytic perspectives, willingness-to-pay (WTP) thresholds, and time horizons used in cost-effectiveness studies. Indirect costs, including caregiver burden and productivity loss, were infrequently reported.</p><p><strong>Conclusion: </strong>Although available evidence suggests that RRD is generally associated with favourable cost-effectiveness outcomes, conclusions are limited by methodological heterogeneity, predominance of evidence from high-income settings, and inconsistent reporting of indirect costs. Broader and more standardized economic evaluations, particularly in non-Western settings, are needed to better characterize the global economic impact of RRD repair.</p>","PeriodicalId":47313,"journal":{"name":"ClinicoEconomics and Outcomes Research","volume":"18 ","pages":"559354"},"PeriodicalIF":2.6,"publicationDate":"2026-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13654260/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149169924","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Economic Burden of treated Lower-Risk Myelodysplastic Syndromes in France: A Population-Based Study.","authors":"Maud D'Aveni, Jérôme Fernandes, Mélanie Chartier, Nicolas Pagès, Aurélie Schmidt, Léa Webert, François-Emery Cotté, Thibault Comont","doi":"10.2147/CEOR.S619291","DOIUrl":"10.2147/CEOR.S619291","url":null,"abstract":"<p><strong>Background: </strong>Updated data are needed to understand the current implications of Low-risk Myelodysplastic syndromes (LR-MDS) on healthcare resource use (HCRU) and associated costs. Objectives of this study were to describe these outcomes over time but also to compare costs according to transfusion dependency at baseline.</p><p><strong>Methods: </strong>A retrospective observational study was carried out using the ESND (\"Echantillon National du SNDS\") database. All incident adults newly treated for MDS were included between 2018 and 2022. Patients were followed from the start of specific treatment to death, the end of the study period, or loss to follow-up (FU). HCRU and related costs were described according to French National Health Insurance perspective in euro 2022. Reimbursed total costs per patient were computed per year of follow-up and according to transfusion status.</p><p><strong>Results: </strong>Over the study period, 267 patients newly treated for LR-MDS were included. Median total costs related to HCRU/patient for the entire FU period were estimated at €41,698 (IQR: 19,093; 84,111) with a median cost/patient/year of FU ranging from €26,693 (Y1) to €20,418 (Y3). Main cost drivers were hospitalizations and use of specific drugs. TD patients had more hospitalizations (94.4% vs 89.3%) and transfusions (77.5% vs 47.4%), leading to statistically significantly higher costs after treatment initiation.</p><p><strong>Conclusion: </strong>This nationwide study is the largest describing the economic burden of treated LR-MDS patients in France using administrative claims data. Elevated costs and substantial burden for treated patients and the health care system were observed. Transfusion dependence was associated with incremental health care resource utilization and related costs. Further studies are needed to assess the impact of emerging therapies in this indication.</p>","PeriodicalId":47313,"journal":{"name":"ClinicoEconomics and Outcomes Research","volume":"18 ","pages":"619291"},"PeriodicalIF":2.6,"publicationDate":"2026-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13645682/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149138791","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Short-Term Cost per Responder of Lebrikizumab versus Tralokinumab for Moderate-to-Severe Atopic Dermatitis in Saudi Arabia: A Model-Based Payer Analysis.","authors":"Hamad Almutlaq","doi":"10.2147/CEOR.S641333","DOIUrl":"10.2147/CEOR.S641333","url":null,"abstract":"<p><strong>Purpose: </strong>Atopic dermatitis (AD) imposes a clinical and economic burden, and biologic acquisition costs influence payer decisions. This study compared the short-term cost per responder of lebrikizumab and tralokinumab for moderate-to-severe AD in Saudi Arabia.</p><p><strong>Methods: </strong>A cost-per-responder model used a Saudi payer perspective and publicly available Saudi Food and Drug Authority (SFDA) list prices, which may differ from negotiated or tender prices. Lebrikizumab 250 mg every two weeks and tralokinumab 300 mg every two weeks were compared before week-16 response assessment. Response probabilities were obtained from the 2025 network meta-analysis by Silverberg et al. EASI probabilities were reported directly; IGA 0/1 and pruritus NRS ≥4 probabilities were reconstructed from NMA relative effects and placebo risks. The primary endpoint was EASI 75 at week 16. In addition to the 16-week framework, exploratory pruritus analyses aligned week-4 response with costs through weeks 0 and 2, separately assessed inclusion of the week-4 dose, and tested whole-pack acquisition. Deterministic sensitivity, price-scenario, threshold, and fixed-budget analyses were performed.</p><p><strong>Result: </strong>Lebrikizumab had higher modelled response probabilities across endpoints, whereas tralokinumab had a lower administered-dose acquisition cost before week 16 (SAR 19,858.50 vs SAR 44,130). Tralokinumab had lower costs per responder for EASI 50 (SAR 41,632 vs SAR 69,169), EASI 75 (SAR 63,649 vs SAR 94,903), EASI 90 (SAR 113,477 vs SAR 148,087), and IGA 0/1 (SAR 71,346 vs SAR 96,876). After correction of the available-case placebo denominator, week-4 pruritus response probabilities were 29.6% for lebrikizumab and 13.5% for tralokinumab. Using 16-week administered-dose costs, cost per pruritus responder was similar but marginally lower with tralokinumab (SAR 147,214 vs SAR 149,128). In the time-aligned analysis before the week-4 assessment, fractional-pack costing favoured tralokinumab (SAR 49,071 vs SAR 59,651), whereas whole-pack costing favoured lebrikizumab (SAR 59,651 vs SAR 65,429).</p><p><strong>Conclusion: </strong>Under the modelled public Saudi list prices, tralokinumab had a lower short-term cost per responder for the week-16 skin-response endpoints. The pruritus result was exploratory and changed according to the cost horizon and pack-purchasing convention; it does not establish a consistent economic advantage for either treatment. The findings are price dependent and should not be interpreted as overall clinical superiority or long-term cost-effectiveness.</p>","PeriodicalId":47313,"journal":{"name":"ClinicoEconomics and Outcomes Research","volume":"18 ","pages":"641333"},"PeriodicalIF":2.6,"publicationDate":"2026-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13615795/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149064911","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cost-Effectiveness and Budget Impact of Cardioform versus Amplatzer and Medical Therapy Alone for Patent Foramen Ovale Closure: A UK Payer Perspective.","authors":"James R Bentham, Jet Neervoort, Timon Louwsma, Lambertus F Wolters, Julie Lyon, Erik J Landaas, Mitesh Nakum","doi":"10.2147/CEOR.S625089","DOIUrl":"10.2147/CEOR.S625089","url":null,"abstract":"<p><strong>Purpose: </strong>This study evaluated the cost-effectiveness and budget impact of two patent foramen ovale (PFO) closure devices and medical management for the prevention of recurrent PFO-associated strokes in the UK.</p><p><strong>Patients and methods: </strong>We used a Markov model to simulate 1000 individuals with a history of PFO-associated stroke over a five-year time horizon. Treatment options included GORE^® CARDIOFORM Septal Occluder (GSO Device), Amplatzer™ Talisman PFO Occluder (ATO Device), and Medical Therapy Alone. Effectiveness data were drawn from the REDUCE and RESPECT trials and prior cost-effectiveness analyses (CEAs). No head-to-head clinical trial comparing the ATO and GSO Device was identified; therefore, comparative clinical effectiveness estimates were derived from a matching-adjusted indirect comparison (MAIC). Costs were assessed from a UK payer perspective (2023 GBP). Outcomes included quality-adjusted life-years (QALYs), prevented strokes, incremental cost-effectiveness ratio (ICER), and budget impact.</p><p><strong>Results: </strong>GSO Device was estimated to be cost-saving and generate 24.66 additional QALYs versus ATO Device (dominant ICER) over five years and in a cohort of 1000 patients. Compared with Medical Therapy Alone, it provided 406.66 additional QALYs at an ICER of £14,343/QALY. It also prevented 27.86 and 67.05 strokes versus ATO Device and Medical Therapy Alone, respectively.</p><p><strong>Conclusion: </strong>The use of GSO Device is a cost-effective option for the prevention of secondary PFO-associated strokes, with favorable estimated clinical outcomes. Future studies providing direct comparative evidence between GSO and ATO could further inform the relative clinical and cost-effectiveness of available PFO closure devices.</p>","PeriodicalId":47313,"journal":{"name":"ClinicoEconomics and Outcomes Research","volume":"18 ","pages":"625089"},"PeriodicalIF":2.6,"publicationDate":"2026-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13590004/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149013006","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quality of Life Changes in Respiratory Infection Trajectory with Point of Care Testing During Clinical Consultation.","authors":"Paula Rojas-Garcia, Reyes Lorente, Marino J González, Carmelo A Juárez-Castelló, Fernando Antoñanzas, Pim W M Van Dorst, Clazinus Veijer, Simon Van der Pol, Christopher C Butler, Alike W Van der Velden, Herman Goossens, Antoinette D I Van Asselt, Maarten J Postma","doi":"10.2147/CEOR.S626662","DOIUrl":"10.2147/CEOR.S626662","url":null,"abstract":"<p><strong>Background: </strong>This study evaluates the impact of a point-of-care (POC) testing strategy and subsequent treatments for respiratory tract infections (RTIs) on patients' health-related quality of life (QoL).</p><p><strong>Materials and methods: </strong>The PRUDENCE trial, with a sample of 2639 patients, showed that a POC testing strategy for RTIs (C-reactive protein, group A streptococcus, and influenza A/B, with optional SARS-CoV-2 testing) did not reduce antibiotic prescribing nor had a measurable impact on time to patient recovery compared to usual care. However, differences in patient-reported QoL may still exist, as utility can capture more subtle changes in symptom burden and well-being. The EQ-5D-5L questionnaire was completed by PRUDENCE trial patients at days 1, 14, and 28 of follow-up. Quality-adjusted life-year (QALY) gains were estimated. Static and dynamic analyses were performed to assess changes in utility values.</p><p><strong>Results: </strong>No statistically significant differences in utility scores were observed between the usual care and POC testing groups at any time point during the 28-day study period. However, both groups demonstrated statistically significant improvements in patient-reported utility scores over the 28-day period, corresponding to gains of 0.00502 QALYs in the usual care group and 0.00525 QALYs in the POC testing group. These improvements were already apparent by day 14 of follow-up.</p><p><strong>Conclusion: </strong>Improvements in utility scores over time were similar in both groups and likely reflected the natural clinical recovery from RTIs rather than the effect of the diagnostic strategy itself. Measures such as symptom relief, full recovery and side effects may better capture the intervention's impact.</p><p><strong>Trial registration number: </strong>ISRCTN13336322.</p>","PeriodicalId":47313,"journal":{"name":"ClinicoEconomics and Outcomes Research","volume":"18 ","pages":"626662"},"PeriodicalIF":2.6,"publicationDate":"2026-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13544129/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148897949","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"What Does \"Success\" Mean in the Cost-Effectiveness of Fetal Fibronectin Testing? [Response to Letter].","authors":"Dina Abushanab, Nader Al-Dewik, Reem AlNasr, Reem Alenany, Lana Kattan, Ghaith Alali, Alaa Al-Naama, Moza Al-Hail, Thomas Farrell, Haseebur Rahman Khan Mohammed, Wessam Elkassem, Abdulrouf Pallivalapila, Binny Thomas, Daoud Al-Badriyeh","doi":"10.2147/CEOR.S650353","DOIUrl":"10.2147/CEOR.S650353","url":null,"abstract":"","PeriodicalId":47313,"journal":{"name":"ClinicoEconomics and Outcomes Research","volume":"18 ","pages":"650353"},"PeriodicalIF":2.6,"publicationDate":"2026-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13541068/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148888784","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"What Does \"Success\" Mean in the Cost-Effectiveness of Fetal Fibronectin Testing? [Letter].","authors":"Güney Sarıoğlu","doi":"10.2147/CEOR.S647207","DOIUrl":"10.2147/CEOR.S647207","url":null,"abstract":"","PeriodicalId":47313,"journal":{"name":"ClinicoEconomics and Outcomes Research","volume":"18 ","pages":"647207"},"PeriodicalIF":2.6,"publicationDate":"2026-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13526330/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148867315","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}